HA1 (ARHGAP45) Rabbit Polyclonal Antibody
CAT#: TA372703
ARHGAP45 rabbit polyclonal antibody
Size: 25 ul
Need it in bulk or conjugated?
Get a free quote
CNY 1,999.00
CNY 3,280.00
CNY 300.00
CNY 1,430.00
Specifications
Product Data | |
Applications | IHC |
Recommend Dilution | IHC: 10-50 Positive control: Human breast cancer Predicted cell location: Cytoplasm |
Reactivity | Human |
Host | Rabbit |
Clonality | Polyclonal |
Immunogen | Synthetic peptide of human ARHGAP45 |
Formulation | pH7.4 PBS, 0.05% NaN3, 40% Glycerol |
Concentration | lot specific |
Purification | Antigen affinity purification |
Conjugation | Unconjugated |
Storage Condition | Store at -20°C. |
Gene Name | histocompatibility (minor) HA-1 |
Database Link | |
Background | Contains a GTPase activator for the Rho-type GTPases (RhoGAP) domain that would be able to negatively regulate the actin cytoskeleton as well as cell spreading. However, also contains N-terminally a BAR-domin which is able to play an autoinhibitory effect on this RhoGAP activity. Precursor of the histocompatibility antigen HA-1. More generally, minor histocompatibility antigens (mHags) refer to immunogenic peptide which, when complexed with MHC, can generate an immune response after recognition by specific T-cells. The peptides are derived from polymorphic intracellular proteins, which are cleaved by normal pathways of antigen processing. The binding of these peptides to MHC class I or class II molecules and its expression on the cell surface can stimulate T-cell responses and thereby trigger graft rejection or graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation from HLA-identical sibling donor. GVHD is a frequent complication after bone marrow transplantation (BMT), due to mismatch of minor histocompatibility antigen in HLA-matched sibling marrow transplants. Specifically, mismatching for mHag HA-1 which is recognized as immunodominant, is shown to be associated with the development of severe GVHD after HLA-identical BMT. HA-1 is presented to the cell surface by MHC class I HLA-A*0201, but also by other HLA-A alleles. This complex specifically elicits donor-cytotoxic T-lymphocyte (CTL) reactivity against hematologic malignancies after treatment by HLA-identical allogenic BMT. It induces cell recognition and lysis by CTL. |
Synonyms | HA-1; HLA-HA1; KIAA0223 |
Reference Data |
Documents
Product Manuals |
FAQs |
SDS |
Resources
抗体相关资料 |
其它ARHGAP45产品